GASC
MCID: GST053
MIFTS: 79

Gastric Cancer (GASC)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Gastric Cancer

MalaCards integrated aliases for Gastric Cancer:

Name: Gastric Cancer 57 38 12 53 75 37 55 15
Stomach Cancer 12 76 53 75 29 43 15
Stomach Carcinoma 12 53 15 73
Gastric Carcinoma 12 55 15
Malignant Tumor of Lesser Curve of Stomach 12 73
Malignant Neoplasm of Body of Stomach 12 73
Neoplasm of Stomach 29 6
Stomach Neoplasms 44 73
Malignant Neoplasm of Lesser Curve of Stomach 12
Malignant Tumor of Greater Curve of Stomach 12
Malignant Tumor of Body of Stomach 12
Ca Greater Curvature of Stomach 12
Ca Lesser Curvature - Stomach 12
Malignant Neoplasm of Stomach 73
Gastric Cancer Intestinal 75
Gastric Cancer, Somatic 57
Adult Stomach Carcinoma 53
Cancer of the Stomach 12
Carcinoma of Stomach 12
Adult Stomach Cancer 53
Ca Body - Stomach 12
Gastric Neoplasm 12
Cancer, Gastric 40
Gasc 75

Characteristics:

HPO:

32
gastric cancer:
Inheritance somatic mutation


Classifications:



Summaries for Gastric Cancer

NIH Rare Diseases : 53 Stomach cancer, also called gastric cancer, is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the stomach. Most people with early stomach cancer have no signs or symptoms of the condition. In advanced stages, symptoms may include indigestion; nausea and vomiting; difficulty swallowing; feeling full after eating small amounts of food; loss of appetite; vomiting blood; fatigue; and/or weight loss. Most cases of stomach cancer occur sporadically in people with little to no family history of the condition; however, approximately 10% of stomach cancers are considered "familial." Although the underlying cause of some familial cases is unknown, genetic changes (mutations) are identified in a subset of people affected by stomach cancer. Hereditary cancer syndromes associated with a predisposition to stomach cancer include hereditary diffuse gastric cancer, Lynch syndrome, Li-Fraumeni syndrome, familial adenomatous polyposis, and Peutz-Jeghers syndrome. In other families, a cluster of stomach cancers may be due to a combination of gene(s) and/or other shared factors such as environment and lifestyle. The best treatment options for stomach cancer depend on many factors including the stage of the condition and may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Gastric Cancer, also known as stomach cancer, is related to gastric adenocarcinoma and adenocarcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gastric Cancer is APC (APC, WNT Signaling Pathway Regulator), and among its related pathways/superpathways are Gastric cancer and PI3K-Akt signaling pathway. The drugs Cyramza and Herceptin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and lung, and related phenotypes are stomach cancer and increased level of l-fucose in urine

Disease Ontology : 12 A gastrointestinal system cancer that is located in the stomach.

OMIM : 57 In a review article on the genetic predisposition to gastric cancer, Bevan and Houlston (1999) concluded that several genes may be associated with an increased risk of gastric cancer. Gastric cancer is a manifestation of a number of inherited cancer predisposition syndromes, including hereditary nonpolyposis colon cancer (HNPCC1; see 120435), familial adenomatous polyposis (FAP; 175100), Peutz-Jeghers syndrome (PJS; 175200), Cowden disease (CD; 158350), and the Li-Fraumeni syndrome (151623). See also hereditary diffuse gastric cancer (HDGC; 137215). Canedo et al. (2007) provided a review of genetic susceptibility to gastric cancer in patients infected with Helicobacter pylori (see 600263). (613659)

MedlinePlus : 43 The stomach is an organ between the esophagus and the small intestine. It mixes food with stomach acid and helps digest protein. Stomach cancer mostly affects older people - two-thirds of people who have it are over age 65. Your risk of getting it is also higher if you Have had a Helicobacter pylori infection Have had stomach inflammation Are a man Eat lots of salted, smoked, or pickled foods Smoke cigarettes Have a family history of stomach cancer It is hard to diagnose stomach cancer in its early stages. Indigestion and stomach discomfort can be symptoms of early cancer, but other problems can cause the same symptoms. In advanced cases, there may be blood in your stool, vomiting, unexplained weight loss, jaundice, or trouble swallowing. Doctors diagnose stomach cancer with a physical exam, blood and imaging tests, an endoscopy, and a biopsy. Because it is often found late, it can be hard to treat stomach cancer. Treatment options include surgery, chemotherapy, radiation or a combination. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 75 Gastric cancer: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

Wikipedia : 76 Stomach cancer, also known as gastric cancer, is a cancer which develops from the lining of the stomach.... more...

Related Diseases for Gastric Cancer

Diseases related to Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 559)
# Related Disease Score Top Affiliating Genes
1 gastric adenocarcinoma 33.1 APC CTNNB1 ERBB2 FGFR2 KRAS PIK3CA
2 adenocarcinoma 31.8 APC CTNNB1 ERBB2 FGFR2 KRAS PIK3CA
3 colorectal cancer 31.6 APC CTNNB1 ERBB2 KRAS MIR106B MIR141
4 breast cancer 31.5 APC CTNNB1 ERBB2 FGFR2 KRAS MIR141
5 adenoma 31.2 APC CTNNB1 KRAS MUTYH
6 prostate cancer 31.2 CTNNB1 ERBB2 FGFR2 KLF6 KRAS MIR106B
7 esophageal cancer 31.2 CTNNB1 ERBB2 KRAS MIR203A MIR21 MIR34A
8 hepatocellular carcinoma 31.1 APC CTNNB1 KRAS MIR106B MIR141 MIR145
9 lung cancer 31.1 ERBB2 FGFR2 IRF1 KRAS MIR141 MIR145
10 pancreatic cancer 31.0 CTNNB1 ERBB2 KRAS MIR203A MIR21 MIR221
11 melanoma 30.9 MIR141 MIR200C MIR221 MIR27A MIR34A
12 familial adenomatous polyposis 30.9 APC CTNNB1 KRAS MUTYH
13 lynch syndrome 30.8 APC CTNNB1 KRAS MUTYH
14 cholangiocarcinoma 30.8 APC CTNNB1 ERBB2 KRAS MIR141 MIR21
15 bladder cancer 30.7 ERBB2 KRAS MIR145 MIR203A MIR21 MIR221
16 adamantinoma of long bones 30.6 APC CTNNB1 ERBB2 KRAS MIR141 MIR200C
17 cervical cancer 30.6 CTNNB1 ERBB2 IRF1 MIR21 PIK3CA
18 lung cancer susceptibility 3 30.6 APC CTNNB1 ERBB2 KLF6 KRAS PIK3CA
19 glioma 30.5 ERBB2 MIR21 MIR221 MIR25 MIR34A PIK3CA
20 respiratory system cancer 30.4 CTNNB1 ERBB2 KRAS PIK3CA
21 adenoid cystic carcinoma 30.4 CTNNB1 ERBB2 KRAS PIK3CA
22 colorectal adenoma 30.3 APC CTNNB1 KRAS MUTYH
23 intestinal disease 30.3 CTNNB1 KRAS MUTYH PIK3CA
24 kidney cancer 30.3 MIR106B MIR141 MIR200C MIR21 MIR27A
25 pancreatic ductal adenocarcinoma 30.3 MIR141 MIR145 MIR203A MIR21 MIR221
26 leukemia, chronic lymphocytic 2 30.2 KRAS MIR106B MIR145 MIR34A
27 ovarian cancer 1 30.2 ERBB2 KRAS PIK3CA
28 intrahepatic cholangiocarcinoma 30.2 CTNNB1 FGFR2 KRAS
29 desmoid tumor 30.1 APC CTNNB1
30 attenuated familial adenomatous polyposis 30.0 APC MUTYH
31 gastric cancer, hereditary diffuse 12.8
32 diffuse gastric cancer 12.5
33 microinvasive gastric cancer 12.4
34 stomach carcinoma in situ 12.3
35 epstein-barr virus-associated gastric carcinoma 12.2
36 carcinoma of stomach, salivary gland type 12.2
37 undifferentiated carcinoma of stomach 12.2
38 gastric adenocarcinoma and proximal polyposis of the stomach 11.4
39 li-fraumeni syndrome 11.4
40 li-fraumeni syndrome 2 11.4
41 gastric squamous cell carcinoma 11.1
42 gastric adenosquamous carcinoma 11.1
43 gastric small cell carcinoma 11.1
44 stomach cancer, childhood 11.1
45 gastric linitis plastica 11.1
46 gastric fundus cancer 11.0
47 gastric body carcinoma 11.0
48 small intestine cancer 11.0
49 b cell deficiency 11.0
50 familial stomach cancer 11.0

Comorbidity relations with Gastric Cancer via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Gastric Fundus Cancer
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Neutropenia
Protein-Energy Malnutrition Pylorus Cancer
Stomach Carcinoma in Situ

Graphical network of the top 20 diseases related to Gastric Cancer:



Diseases related to Gastric Cancer

Symptoms & Phenotypes for Gastric Cancer

Clinical features from OMIM:

613659

Human phenotypes related to Gastric Cancer:

32
# Description HPO Frequency HPO Source Accession
1 stomach cancer 32 HP:0012126
2 increased level of l-fucose in urine 32 HP:0410067

UMLS symptoms related to Gastric Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Gastric Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.56 APC CTNNB1 ERBB2 FGFR2 IRF1 KLF6
2 neoplasm MP:0002006 9.23 APC CTNNB1 ERBB2 FGFR2 IRF1 KRAS

Drugs & Therapeutics for Gastric Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Cyramza 18 49 RAMUCIRUMAB Eli Lilly April 2014
2
Herceptin 18 49 TRASTUZUMAB Genentech October 1998
3
Iressa 18 49 GEFITINIB AstraZeneca May 2003

Drugs for Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 583)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
2
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
3
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 61825-94-3 43805 6857599 5310940 9887054
4
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 154361-50-9 60953
5
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
6
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 117976-89-3 5029
7
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
8
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
9
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
10
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 100986-85-4 149096
11
Ofloxacin Approved Phase 4,Phase 3,Phase 1 82419-36-1 4583
12
Pravastatin Approved Phase 4 81093-37-0 54687
13
Pantoprazole Approved Phase 4,Not Applicable 102625-70-7 4679
14
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
15
Ticlopidine Approved Phase 4 55142-85-3 5472
16
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
17
Iron Approved Phase 4,Phase 3,Not Applicable 7439-89-6 23925
18
Tocopherol Approved, Investigational Phase 4,Phase 3,Not Applicable 1406-66-2 14986
19
Histamine Approved, Investigational Phase 4,Phase 1,Not Applicable 51-45-6, 75614-87-8 774
20
Famotidine Approved Phase 4,Phase 1 76824-35-6 3325
21
Lansoprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 103577-45-3 3883
22
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 103577-45-3, 138530-94-6 9578005
23
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
24
Metronidazole Approved Phase 4,Phase 3,Phase 1 443-48-1 4173
25
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 73590-58-6 4594
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
27
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
28
Etomidate Approved Phase 4 33125-97-2 667484 36339
29
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
30
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
31
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
32
Tinidazole Approved, Investigational Phase 4,Phase 3 19387-91-8 5479
33
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6
34
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51110-01-1, 38916-34-6 53481605
35
Floxuridine Approved Phase 4,Phase 3,Phase 2,Phase 1 50-91-9 5790
36
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3 7487-88-9 24083
37
Simethicone Approved Phase 4 8050-81-5
38
Morphine Approved, Investigational Phase 4 57-27-2 5288826
39
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 175805 71273
40
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
41
Coal tar Approved Phase 4 8007-45-2
42
Tetracycline Approved, Vet_approved Phase 4,Phase 3 60-54-8 5353990
43
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
44
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
45
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
46
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 93-14-1 3516
47
Pasireotide Approved Phase 4,Phase 1 396091-73-9 9941444
48
Loperamide Approved Phase 4,Not Applicable 53179-11-6 3955
49
Pectin Approved, Investigational, Vet_approved Phase 4 9000-69-5 441476
50
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3 564-25-0 54671203

Interventional clinical trials:

(show top 50) (show all 1898)
# Name Status NCT ID Phase Drugs
1 Gastrectomy Plus Prophylactic Cholecystectomy in Gastric Cancer Surgery Unknown status NCT00757640 Phase 4
2 A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy Unknown status NCT02776527 Phase 4 Apatinib Mesylate Tablets
3 Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients Unknown status NCT01910948 Phase 4 omega-3 polyunsaturated fatty acids
4 Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer Unknown status NCT02401971 Phase 4 Thalidomide;CPT-11
5 Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
6 Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
7 Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
8 Early Jejunostomy Nutrition Minimizes Time to Chemotherapy Unknown status NCT01766765 Phase 4
9 Community-based Helicobacter Pylori Eradication Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
10 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Unknown status NCT02426034 Phase 4 Apatinib
11 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
12 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
13 Iron Replacement in Oesophagogastric Neoplasia Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
14 A Comparison of pCLE Based Targeted Biopsy and WLE Based Standard Biopsy in Staging the Operative Link on Gastric Intestinal Metaplasia (OLGIM): A Randomized,Cross-over Study Unknown status NCT02930616 Phase 4
15 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
16 Effect of Helicobacter Pylori on the Availability of Vitamin E and C Unknown status NCT00303160 Phase 4 vitamin C & E supplements
17 Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection Unknown status NCT01308177 Phase 4 Ecabet
18 Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
19 Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
20 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
21 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
22 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
23 Combined Use of Etomidate and Propofol in Painless Gastroscopy. Unknown status NCT01913054 Phase 4 Fentanyl Injection;Etomidate Fat Emulsion Injection;Propofol Injection
24 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
25 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection Completed NCT01914692 Phase 4 Somatostatin
26 RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients Completed NCT01401075 Phase 4 mistletoe extract;doxifluridine
27 Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor Completed NCT01579071 Phase 4
28 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
29 Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy Completed NCT01653171 Phase 4 Water (Placebo);Simethicone;N-acetylcysteine 500 mg;N-acetylcysteine 1000 mg
30 Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia Completed NCT01471756 Phase 4
31 Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02458573 Phase 4
32 Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study- Completed NCT01234272 Phase 4 morphine;Ropivacaine
33 The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02164448 Phase 4 the dexmedetomidine group;the control group
34 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
35 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
36 Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4 10-day sequential treatment;10-day concomitant therapy
37 The Effect of Nutritional Counseling for Cancer Patients Completed NCT01962272 Phase 4
38 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
39 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
40 The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study Completed NCT00885417 Phase 4 Cravit-based sequential therapy
41 Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori Completed NCT01042184 Phase 4 Sequential therapy for 14 days;Sequential therapy for 10 days;Triple therapy for 14 days
42 The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection Completed NCT01032655 Phase 4 susceptibility test guided sequential therapy
43 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
44 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
45 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
46 Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Recruiting NCT02047994 Phase 4 Triple therapy
47 Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations Recruiting NCT03475589 Phase 4 apatinib
48 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
49 Laparoscopic Versus Open Resection of Cancer Stomach Recruiting NCT02789826 Phase 4
50 Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection Recruiting NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin

Search NIH Clinical Center for Gastric Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: stomach neoplasms

Genetic Tests for Gastric Cancer

Genetic tests related to Gastric Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Stomach 29 APC CASP10 ERBB2 FGFR2 IRF1 KLF6 MUTYH PIK3CA
2 Stomach Cancer 29

Anatomical Context for Gastric Cancer

MalaCards organs/tissues related to Gastric Cancer:

41
Lymph Node, Liver, Lung, Endothelial, Testes, Breast, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Gastric Cancer:

19
The Stomach

Publications for Gastric Cancer

Articles related to Gastric Cancer:

(show top 50) (show all 12605)
# Title Authors Year
1
Aurora kinase B inhibitor barasertib (AZD1152) inhibits glucose metabolism in gastric cancer cells. ( 30540594 )
2019
2
Corrigendum to "Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer" [Transl Oncol 10/3 (2017) 431-441]. ( 30553293 )
2019
3
Up-Regulation of MiR-1915 Inhibits Proliferation, Invasion, and Migration of Helicobacter pylori-Infected Gastric Cancer Cells via Targeting RAGE. ( 30554489 )
2019
4
Characterization of a new exopolysaccharide produced by Halorubrum sp. TBZ112 and evaluation of its anti-proliferative effect on gastric cancer cells. ( 30555767 )
2019
5
Identifying the barriers to gastric cancer care at safety-net hospitals: A novel comparison of a safety-net hospital to a neighboring quaternary referral academic center in the same healthcare system. ( 30481370 )
2019
6
Long non-coding RNA HOTAIR mediates the switching of histone H3 lysine 27 acetylation to methylation to promote epithelial-to-mesenchymal transition in gastric cancer. ( 30431069 )
2019
7
Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer. ( 30444009 )
2019
8
Feasibility of intensity-modulated radiotherapy to treat gastric cancer. ( 30479581 )
2019
9
IL-21R functions as an oncogenic factor and is regulated by the lncRNA MALAT1/miR-125a-3p axis in gastric cancer. ( 30387833 )
2019
10
Novel 3-(2,6,9-trisubstituted-9H-purine)-8-chalcone derivatives as potent anti-gastric cancer agents: Design, synthesis and structural optimization. ( 30388465 )
2019
11
KIF14 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in human gastric cancer. ( 30404039 )
2019
12
Paclitaxel‑resistant gastric cancer MGC‑803 cells promote epithelial‑to‑mesenchymal transition and chemoresistance in paclitaxel‑sensitive cells via exosomal delivery of miR‑155‑5p. ( 30365045 )
2019
13
LncRNA MALAT1 potentiates autophagy‑associated cisplatin resistance by regulating the microRNA‑30b/autophagy‑related gene 5 axis in gastric cancer. ( 30365113 )
2019
14
TCF21 inhibits proliferation and chemoresistance through the AKT pathway in human gastric cancer. ( 30296564 )
2019
15
Metformin suppresses gastric cancer progression through calmodulin‑like protein 3 secreted from tumor‑associated fibroblasts. ( 30320344 )
2019
16
The diagnostic value of circulating microRNAs as a biomarker for gastric cancer: A meta‑analysis. ( 30320349 )
2019
17
GLIS2 redundancy causes chemoresistance and poor prognosis of gastric cancer based on co‑expression network analysis. ( 30320360 )
2019
18
A method of detecting two tumor markers (p-hydroxybenzoic acid and p-cresol) in human urine using a porous magnetic <beta>-cyclodextrine polymer as solid phase extractant, an alternative for early gastric cancer diagnosis. ( 30262042 )
2019
19
Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2. ( 30266498 )
2019
20
HOXA5 inhibits tumor growth of gastric cancer under the regulation of microRNA-196a. ( 30267809 )
2019
21
Suppression of BMX-ARHGAP fusion gene inhibits epithelial-mesenchymal transition in gastric cancer cells via RhoA-mediated blockade of JAK/STAT axis. ( 30216523 )
2019
22
Curcumin derivative L6H4 inhibits proliferation and invasion of gastric cancer cell line BGC-823. ( 30242876 )
2019
23
MicroRNA-133a inhibits gastric cancer cells growth, migration, and epithelial-mesenchymal transition process by targeting presenilin 1. ( 30161272 )
2019
24
Potential therapeutic effects of curcumin in gastric cancer. ( 30191991 )
2019
25
CircRBMS3 promotes gastric cancer tumorigenesis by regulating miR-153-SNAI1 axis. ( 30132886 )
2019
26
Global estimate of gastric cancer in Helicobacter pylori-infected population: A systematic review and meta-analysis. ( 30132888 )
2019
27
Does Helicobacter pylori eradication therapy to prevent gastric cancer increase all-cause mortality? ( 30152520 )
2019
28
Risk Factors for Anastomotic Leakage of Esophagojejunostomy after Laparoscopy-Assisted Total Gastrectomy for Gastric Cancer. ( 28441658 )
2018
29
Isolated breast metastasis from gastric cancer in a male patient. ( 29302921 )
2018
30
GSDME mediates caspase-3-dependent pyroptosis in gastric cancer. ( 29183726 )
2018
31
VDR independent induction of acid-sphingomyelinase by 1,23(OH)<sub>2</sub>D<sub>3</sub>in gastric cancer cells: Impact on apoptosis and cell morphology. ( 29158006 )
2018
32
Overexpression of NEK3 is associated with poor prognosis in patients with gastric cancer. ( 29504992 )
2018
33
Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. ( 29706558 )
2018
34
Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand MA8ori. ( 29589180 )
2018
35
Role of germline aberrations affecting<i>CTNNA1</i>,<i>MAP3K6</i>and<i>MYD88</i>in gastric cancer susceptibility. ( 29330337 )
2018
36
MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1. ( 29054762 )
2018
37
Superficial Spreading-type Gastric Cancer with <i>Situs Inversus Totalis</i>. ( 29695579 )
2018
38
Upregulation of ZBTB7A exhibits a tumor suppressive role in gastric cancer cells. ( 29207095 )
2018
39
Discriminating gastric cancer and gastric ulcer using human plasma amino acid metabolic profile. ( 29626382 )
2018
40
Inhibition of two gastric cancer cell lines induced by fucoxanthin involves downregulation of Mcl-1 and STAT3. ( 29110251 )
2018
41
Human epidermal growth factor receptor 2 expressions and Janus-activated kinase/signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway may be associated with clinicopathological features and prognosis of gastric cancer. ( 29970682 )
2018
42
Long noncoding RNA LINC00978 promotes cancer growth and acts as a diagnostic biomarker in gastric cancer. ( 29271006 )
2018
43
DDIT4 promotes gastric cancer proliferation and tumorigenesis through the p53 and MAPK pathways. ( 29976242 )
2018
44
Impact of SNP-SNP interactions of DNA repair gene<i>ERCC5</i>and metabolic gene<i>GSTP1</i>on gastric cancer/atrophic gastritis risk in a Chinese population. ( 29434449 )
2018
45
FBXO31 Suppresses Gastric Cancer EMT by Targeting Snail1 for Proteasomal Degradation. ( 29117943 )
2018
46
Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. ( 29306868 )
2018
47
Robot-assisted distal gastrectomy with lymph node dissection for gastric cancer in a patient with situs inversus partialis: a case report with video file. ( 29441475 )
2018
48
Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human gastric cancer. ( 29106391 )
2018
49
STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy. ( 29329543 )
2018
50
SPP1 rs4754 and its epistatic interactions with SPARC polymorphisms in gastric cancer susceptibility. ( 28962925 )
2018

Variations for Gastric Cancer

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer:

75 (show all 19)
# Symbol AA change Variation ID SNP ID
1 APC p.Gly817Cys VAR_005035
2 APC p.Ile880Thr VAR_005036
3 APC p.Asn942Asp VAR_005039
4 APC p.Gly1120Glu VAR_005042 rs28933379
5 APC p.Arg1171His VAR_005043 rs372481703
6 APC p.Phe1197Ser VAR_005045
7 APC p.Ile1259Thr VAR_005046
8 APC p.Gly1312Glu VAR_005050
9 APC p.Val1326Ala VAR_005052
10 CASP10 p.Met147Thr VAR_037428 rs121909776
11 IRF1 p.Met8Leu VAR_065134 rs121912469
12 IRF1 p.Trp11Arg VAR_065135 rs121912470
13 KRAS p.Gly12Val VAR_006840 rs121913529
14 KRAS p.Gly12Asp VAR_016026 rs121913529
15 KRAS p.Gly12Ser VAR_016028 rs121913530
16 KRAS p.Gly13Asp VAR_016029 rs112445441
17 KRAS p.Ala59Thr VAR_016030 rs121913528
18 KRAS p.Lys5Asn VAR_064849 rs104894361
19 MUTYH p.Pro402Ser VAR_026049 rs121908382

ClinVar genetic disease variations for Gastric Cancer:

6 (show top 50) (show all 87)
# Gene Variation Type Significance SNP ID Assembly